GenomeScan is partnering with Olink Proteomics to bring proteomics to the next level by enabling high-throughput analysis of thousands of proteins, while using less than a drop of blood.
Olink’s PEA technology that is based on dual antibody recognition results in the coupling of DNA oligonucleotides and boasts exceptional levels of specificity, sensitivity and dynamic range.
By combining different omics approaches, GenomeScan helps facilitates researchers in identifying the regulators of biological processes, identifying new targets for drug discovery, evaluating therapeutic interventions, and identifying biomarkers that can be used for diagnosis, prognosis, and disease monitoring, leading to more precise and effective treatments.
This strategic move allows us to better integrate into this unique community, empowering us to strengthen collaborations with leading researchers and provide exceptional, on-site support to our partners in life science research and pharmaceutical development.
On Tuesday 16 December, Leiden University Medical Center welcomed His Majesty King Willem-Alexander and Minister Jan Anthonie Bruijn of the Ministry of Health, Welfare and Sport...
Vanmiddag nam minister Jan Anthonie Bruijn van het ministerie van Volksgezondheid, Welzijn en Sport in Leiden, bij het LUMC, het rapport ‘Nederland in de voorhoede: rode biotech...